Eton Pharmaceuticals, Inc.
ETON
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.6B
$58.45
▼ -2.42%
P/E
125.81
Mkt Cap
$1.6B
52-Wk Range
$14.27–$66.37
52-Week Range
$14.27 - $66.37
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 228.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized focus on rare diseases with limited competition and higher pricing power
- Efficient development strategy using reformulations and novel delivery systems to reduce time-to-market
- Established FDA-approved product portfolio generating near-term revenue and cash flow
- Niche market expertise in underserved patient populations with strong physician relationships
Bear Case
2 risks
- Average volatility.
- Growth premium of 2.1x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Growth
Strong growth ahead
Expansion of approved product sales through increased market penetration and awareness
Value
Growth premium of 2.1x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+95.2% over 3m
Quality
Strong
High-growth business (82% revenue growth, 58% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying ETON right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of $0.43 vs $0.19 consensus (+126.5% surprise). Revenue of $37.6M vs $27.1M expected (+38.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+126.5%
Revenue trend · last 8Q
—
+59%
+117%
+109%
+118%
+83%
+40%
+99%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$10.3M
$11.6M
$17.3M
$18.9M
$22.5M
$21.3M
$24.3M
$37.6M
Margins · last 8Q
Gross
67.6%
Operating
34.0%
Profit
30.8%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: B. Riley · Aug 14, 2026
vs Industry
How ETON stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related